After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Vaccines represent the single most cost-efficient and equitable way to combat and eradicate
infectious diseases. While traditional licensed vaccines consist of either …

Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

Background A safe, effective vaccine is essential to eradicating human immunodeficiency
virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX …

Introduction The development of an effective vaccine to protect against HIV is a longstanding
global health need complicated by challenges inherent to HIV biology and to the execution …

IgG3 comprises only a minor fraction of IgG and has remained relatively understudied until
recent years. Key physiochemical characteristics of IgG3 include an elongated hinge region …

HIV-1–specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc
receptors. Antibodies of the same epitope specificity but of a different subclass therefore can …

The RV144 trial demonstrated 31% vaccine efficacy at preventing human immunodeficiency
virus (HIV)-1 infection. Antibodies against the HIV-1 envelope variable loops 1 and 2 (Env …

Non-neutralizing antibodies (nnAbs) to HIV-1 show little measurable activity in prevention or
therapy in animal models yet were the only correlate of protection in the RV144 vaccine trial …

The development of an effective AIDS vaccine remains a challenge. Nucleoside-modified
mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of …